King’s College London drug KCL-286 shows Alzheimer’s potential

Targeting DNA damage and brain inflammation

The study focused on DNA double-strand breaks, which are a type of damage that can threaten cell survival and disrupt cell function.

The drug functions by activating a specific protein within the retinoic acid pathway, a system linked to vitamin A usage, gene regulation, and nervous system function.

Unlike most existing treatments that focus on amyloid-beta and tau proteins, this study suggests targeting DNA damage and brain inflammation. These processes may occur during the early stages of the disease.

Expert perspectives on disease-modifying therapy

Maria Goncalves said the drug targets DNA damage and inflammation, which are early processes in Alzheimer's disease. She said these findings show the potential for a disease-modifying therapy rather than just a treatment for symptoms. Professor Corcoran said the drug stimulates the repair of DNA double-strand breaks.

Natasha Hill, one of the first authors of the paper, said that developing an effective treatment requires tackling multiple aspects of the disease.

Repurposing spinal cord injury research

KCL-286 is an orally bioavailable small molecule that was originally developed to treat spinal cord injuries. This discovery prompted the investigation into KCL-286 for Alzheimer's disease.

Professor of Neuroscience Jonathan Corcoran said the team observed this process in their earlier research. The drug stimulates the repair of these breaks, a mechanism the team now applies to Alzheimer's research.

Phase 1 safety trials and future outlook

These initial human trials were designed to assess the safety profile of the experimental treatment.

Despite these early safety findings, the effectiveness of the drug against Alzheimer’s disease in humans remains unproven. ScienceDaily reported on 3 November 2026 that the current Alzheimer’s findings are preclinical. Further research and additional human clinical trials are required to determine if the drug can safely improve patient outcomes or slow disease progression.

Brain barrier and protein buildup research

SciTechDaily reported on 3 November 2026 that animal experiments showed protein buildup damages the brain's protective barrier. This damage provides a potential target for future Alzheimer's treatment.